Document

0000014272-18-000194.txt : 20181025 0000014272-18-000194.hdr.sgml : 20181025 20181025080230 ACCESSION NUMBER: 0000014272-18-000194 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20181025 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20181025 DATE AS OF CHANGE: 20181025 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01136 FILM NUMBER: 181137665 BUSINESS ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 8-K 1 q32018earningsrelease8-k.htm 8-K Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934

Date of Report (Date of earliest event reported): October 25, 2018

BRISTOL-MYERS SQUIBB COMPANY

(Exact Name of Registrant as Specified in its Charter)




Delaware	1-1136	22-0790350
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

430 E. 29th Street, 14FL, New York, N.Y. 10016

(Address of Principal Executive Office)

Registrant’s telephone number, including area code: (212) 546-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):



¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On October 25, 2018, Bristol-Myers Squibb Company (the “Company”) issued a press release announcing its financial results for the third quarter of 2018. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference. Also furnished and incorporated by reference as Exhibit 99.2 is certain supplemental information posted on the Company’s website at www.bms.com.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.




99.1	Press release of Bristol-Myers Squibb Company dated October 25, 2018

99.2	Certain supplemental information posted on Bristol-Myers Squibb Company’s website at www.bms.com not included in the press release.

EXHIBIT INDEX




Exhibit No.	Description

99.1	Press release of Bristol-Myers Squibb Company dated October 25, 2018.

99.2	Certain supplemental information posted on Bristol-Myers Squibb Company’s website at www.bms.com not included in the press release.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



	BRISTOL-MYERS SQUIBB COMPANY

Dated: October 25, 2018	By:	/s/ Katherine R. Kelly
	Name:	Katherine R. Kelly
	Title:	Corporate Secretary

EX-99.1 2 q32018ex991.htm PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED OCTOBER 25, 2018 Exhibit

Exhibit 99.1

Bristol-Myers Squibb Reports Third Quarter Financial Results


•	Increases Third Quarter Revenues 8% to $5.7 Billion


•	Posts Third Quarter GAAP EPS of $1.16 and Non-GAAP EPS of $1.09


•	Presents Important New Clinical Data on Novel, Oral, Selective TYK2 Inhibitor for Potential Treatment of Patients with Moderate to Severe Plaque Psoriasis


•	Additional Opdivo Approvals Including for Adjuvant Treatment of Adult Patients with Melanoma in the European Union


•	Updates on Ongoing Regulatory Review of Opdivo Plus Low-Dose Yervoy in First-Line Lung Cancer


•	Updates 2018 GAAP and Non-GAAP EPS Guidance

(NEW YORK, October 25, 2018) - Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the third quarter of 2018 which were highlighted by strong sales and operating performance along with key regulatory and clinical milestones across the portfolio.

“We had a very good quarter with strong commercial performance and advances in our portfolio through important clinical and regulatory milestones, including exciting new data for psoriasis patients with our internally discovered and developed TYK2 inhibitor,” said Giovanni Caforio, M.D., chairman and chief executive officer, Bristol-Myers Squibb. “Looking forward, we will continue to deliver on our strategy through robust commercial execution and advancing the potential of our increasingly diverse R&D pipeline.”



	Third Quarter
$ amounts in millions, except per share amounts
	2018		2017		Change
Total Revenues	$	5,691	$	5,254	8	%
GAAP Diluted EPS	1.16		0.51		**
Non-GAAP Diluted EPS	1.09		0.75		45	%

** In excess of +/- 100%

THIRD QUARTER FINANCIAL RESULTS


•	Bristol-Myers Squibb posted third quarter 2018 revenues of $5.7 billion, an increase of 8% compared to the same period a year ago. Revenues increased 10% when adjusted for foreign exchange impact.


•	U.S. revenues increased 13% to $3.2 billion in the quarter compared to the same period a year ago. International revenues increased 3%. When adjusted for foreign exchange impact, international revenues increased 6%.


•	Gross margin as a percentage of revenue increased from 69.9% to 71.0% in the quarter primarily due to an inventory charge in the third quarter last year.


•	Marketing, selling and administrative expenses decreased 5% to $1.1 billion in the quarter.


•	Research and development expenses decreased 18% to $1.3 billion in the quarter primarily due to the IFM Therapeutics (IFM) acquisition charges of $310 million in the third quarter last year.


•	The effective tax rate was 11.8% in the quarter, compared to 27.6% in the third quarter last year. The lower tax rate was due to the non-deductible IFM acquisition charges in the third quarter last year and U.S. Tax Reform.


•	The company reported net earnings attributable to Bristol-Myers Squibb of $1.9 billion, or $1.16 per share, in the third quarter compared to net earnings of $845 million, or $0.51 per share, for the same period in 2017.


•	The company reported non-GAAP net earnings attributable to Bristol-Myers Squibb of $1.8 billion, or $1.09 per share, in the third quarter, compared to $1.2 billion, or $0.75 per share, for the same period in 2017. An overview of specified items is discussed under the “Use of Non-GAAP Financial Information” section.


•	Cash, cash equivalents and marketable securities were $8.8 billion, with a net cash position of $1.5 billion, as of September 30, 2018.

THIRD QUARTER PRODUCT AND PIPELINE UPDATE

Product Sales/Business Highlights

Worldwide revenues for the third quarter of 2018, compared to the third quarter of 2017, were driven by:


•	Opdivo, which grew by $528 million or a 42% increase


•	Eliquis, which grew by $345 million or a 28% increase


•	Yervoy, which grew by 18%


•	Orencia, which grew by 7%


•	Sprycel, which decreased by 4%

Opdivo

Regulatory


•	In October, the company provided updates regarding regulatory actions by health authorities in the U.S. and European Union for the ongoing review of its applications for an indication in metastatic first-line non-small cell lung cancer with Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) in patients with tumor mutational burden ≥10 mutations/megabase (link).

•

In August, the company announced the U.S. Food and Drug Administration (FDA) approved Opdivo for the treatment of patients with metastatic small cell lung cancer (SCLC) whose cancer has progressed after platinum-based chemotherapy and at least one other line of therapy. Approval for this indication has been granted under accelerated approval based on overall response rate and duration of response.


•	In July, the company announced the European Commission approved Opdivo for the adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

Clinical


•	In October, at the European Society for Medical Oncology 2018 Annual Congress, the company announced new data and analysis from studies evaluating Opdivo, Yervoy and Opdivo plus Yervoy:


◦	CheckMate -142: Results from a cohort of the Phase 2 trial evaluating Opdivo plus low-dose Yervoy as a first-line treatment in patients with microsatellite instability-high or DNA mismatch repair deficient metastatic colorectal cancer. (link)


◦	CheckMate -067: Results from the Phase 3, double-blind, randomized trial evaluating the combination of Opdivo plus Yervoy or Opdivo monotherapy versus Yervoy monotherapy in patients with previously untreated advanced melanoma. (link)


◦	CheckMate -214: Results from the Phase 3, randomized, open-label study evaluating the combination of Opdivo plus Yervoy versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma. (link)


◦	CheckMate -032: Results from the Phase 1/2 trial evaluating the safety and efficacy of Opdivo as a single agent or in combination with Yervoy in patients with previously treated locally advanced or metastatic urothelial carcinoma. (link)


•	In October, the company announced topline results from CheckMate -331, an open-label, randomized Phase 3 trial of Opdivo versus chemotherapy in patients with relapsed SCLC after first-line platinum-based chemotherapy. (link)

Sprycel

Regulatory


•	In August, the company announced the FDA accepted its supplemental Biologics License Application (sBLA) for Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

Empliciti

Regulatory

•

In September, the company announced the European Medicines Agency validated its type II variation application for Empliciti (elotuzumab) in combination with pomalidomide and low-dose dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI), and have demonstrated disease progression on the last therapy.


•	In August, the company announced the FDA accepted its sBLA for Empliciti in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a PI.

Eliquis

Clinical

•

In August, at the 2018 European Society of Cardiology Congress, the company and Alliance partner, Pfizer, presented 15 Eliquis (apixaban) abstracts. Nine of the studies came from the global real-world data program, ACROPOLIS (Apixaban ExperienCe Through Real-WOrld POpuLatIon Studies), which now includes more than one million patient records, making this the largest body of real world evidence in existence for analyzing the effectiveness and safety of anticoagulants, including Eliquis, among patients with non-valvular atrial fibrillation and venous thromboembolism. (link)

Immunoscience Pipeline

Clinical


•	In September, at the European Academy of Dermatology and Venereology Congress, the company announced results from a Phase 2 study of BMS-986165, an investigational oral, selective TYK2 inhibitor, in patients with moderate to severe plaque psoriasis. These results were also published in the New England Journal of Medicine. (link)

THIRD QUARTER BUSINESS DEVELOPMENT UPDATE


•	In October, the company and Compugen Ltd. announced a clinical trial collaboration to evaluate the safety and tolerability of Compugen’s investigational compound COM701 plus Opdivo in patients with advanced solid tumors.

2018 FINANCIAL GUIDANCE

Bristol-Myers Squibb is increasing its 2018 GAAP EPS guidance range from $2.68 - $2.78 to $3.05 - $3.15 and increasing its non-GAAP EPS guidance range from $3.55 - $3.65 to $3.80 - $3.90. Both GAAP and non-GAAP guidance assume current exchange rates. Key revised 2018 GAAP and non-GAAP line-item guidance assumptions are:


•	Worldwide revenues increasing in the high-single digits.


•	Gross margin as a percentage of revenue to be approximately 71% for both GAAP and non-GAAP.


•	An effective tax rate of approximately 16.5% for GAAP and approximately 17% for non-GAAP.

The financial guidance for 2018 excludes the impact of any potential future strategic acquisitions and divestitures, and any specified items that have not yet been identified and quantified. The non-GAAP 2018 guidance also excludes other specified items as discussed under “Use of Non-GAAP Financial Information.” Details reconciling adjusted non-GAAP amounts with the amounts reflecting specified items are provided in supplemental materials available on the company’s website.

Use of Non-GAAP Financial Information

This press release contains non-GAAP financial measures, including non-GAAP earnings and related EPS information, that are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis. These items are adjusted after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future operating results. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods including restructuring costs, accelerated depreciation and impairment of property, plant and equipment and intangible assets, R&D charges in connection with the acquisition or licensing of third party intellectual property rights, divestiture and equity investment gains or losses, upfront payments from out-licensed assets, pension charges, legal and other contractual settlements and debt redemption gains or losses, among other items. Deferred and current income taxes attributed to these items are also adjusted for considering their individual impact to the overall tax expense, deductibility and jurisdictional tax rates. Non-GAAP information is intended to portray the results of our baseline performance, supplement or enhance management, analysts and investors overall understanding of our underlying financial performance and facilitate comparisons among current, past and future periods. For example, non-GAAP earnings and EPS information is an indication of our baseline performance before items that are considered by us to not be reflective of our ongoing results. In addition, this information is among the primary indicators we use as a basis for evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting for future periods. This information is not intended to be considered in isolation or as a substitute for net earnings or diluted EPS prepared in accordance with GAAP.

Statement on Cautionary Factors

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans and projections regarding the company’s financial position, results of operations, market position, product development and business strategy. These statements may be identified by the fact that they use words such as "anticipate", "estimates", "should", "expect", "guidance", "project", "intend", "plan", "believe" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, effects of the continuing implementation of governmental laws and regulations related to Medicare, Medicaid, Medicaid managed care organizations and entities under the Public Health Service 340B program, pharmaceutical rebates and reimbursement, market factors, competitive product development and approvals, pricing controls and pressures (including changes in rules and practices of managed care groups and institutional and governmental purchasers), economic conditions such as interest rate and currency exchange rate fluctuations, judicial decisions, claims and concerns that may arise regarding the safety and efficacy of in-line products and product candidates, changes to wholesaler inventory levels, variability in data provided by third parties, changes in, and interpretation of, governmental regulations and legislation affecting domestic or foreign operations, including tax obligations, changes to business or tax planning strategies, difficulties and delays in product development, manufacturing or sales including any potential future recalls, patent positions and the ultimate outcome of any litigation matter.

These factors also include the company’s ability to execute successfully its strategic plans, including its business development strategy, the expiration of patents or data protection on certain products, including assumptions about the company’s ability to retain patent exclusivity of certain products, and the impact and result of governmental investigations. There can be no guarantees with respect to pipeline products that future clinical studies will support the data described in this release, that the compounds will receive necessary regulatory approvals, or that they will prove to be commercially successful; nor are there guarantees that regulatory approvals will be sought, or sought within currently expected timeframes, or that contractual milestones will be achieved. For further details and a discussion of these and other risks and uncertainties, see the company's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Company and Conference Call Information

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook.

There will be a conference call on October 25, 2018 at 10:30 a.m. ET during which company executives will review financial information and address inquiries from investors and analysts. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com or by calling the U.S. toll free 866-548-4713 or international 323-794-2093, confirmation code: 3801700. Materials related to the call will be available at the same website prior to the conference call. A replay of the call will be available beginning at 1:45 p.m. ET on October 25, 2018 through 1:45 p.m. ET on November 8, 2018. The replay will also be available through http://investor.bms.com or by calling the U.S. toll free 888-203-1112 or international 719-457-0820, confirmation code: 3801700.

For more information, contact: Media: Lisa McCormick Lavery, 609-252-7602, lisa.mccormicklavery@bms.com; Investor Relations: John Elicker, 609-252-4611, john.elicker@bms.com, Tim Power, 609-252-7509, timothy.power@bms.com or Bill Szablewski, 609-252-5894, william.szablewski@bms.com.

BRISTOL-MYERS SQUIBB COMPANY

PRODUCT REVENUE

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2018 AND 2017

(Unaudited, dollars in millions)



	Worldwide Revenues							U.S. Revenues
	2018			2017		% Change		2018			2017		% Change
Three Months Ended September 30,
Prioritized Brands
Opdivo	$	1,793		$	1,265	42	%	$	1,141		$	778	47	%
Eliquis	1,577			1,232		28	%	917			717		28	%
Orencia	675			632		7	%	474			432		10	%
Sprycel	491			509		(4	)%	267			278		(4	)%
Yervoy	382			323		18	%	278			239		16	%
Empliciti	59			60		(2	)%	41			39		5	%

Established Brands
Baraclude	175			264		(34	)%	6			14		(57	)%
Sustiva Franchise	72			183		(61	)%	5			157		(97	)%
Reyataz Franchise	87			174		(50	)%	27			85		(68	)%
Hepatitis C Franchise	(2		)	73		**		(4		)	24		**
Other Brands	382			539		(29	)%	83			101		(18	)%

Total	$	5,691		$	5,254	8	%	$	3,235		$	2,864	13	%



**	In excess of +/- 100%

BRISTOL-MYERS SQUIBB COMPANY

PRODUCT REVENUE

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2018 AND 2017

(Unaudited, dollars in millions)



	Worldwide Revenues						U.S. Revenues
	2018		2017		% Change		2018			2017		% Change
Nine Months Ended September 30,
Prioritized Brands
Opdivo	$	4,931	$	3,587	37	%	$	3,103		$	2,307	35	%
Eliquis	4,733		3,509		35	%	2,781			2,119		31	%
Orencia	1,979		1,817		9	%	1,360			1,243		9	%
Sprycel	1,464		1,478		(1	)%	791			806		(2	)%
Yervoy	946		975		(3	)%	668			727		(8	)%
Empliciti	178		168		6	%	119			112		6	%

Established Brands
Baraclude	579		819		(29	)%	25			40		(38	)%
Sustiva Franchise	229		555		(59	)%	23			471		(95	)%
Reyataz Franchise	328		555		(41	)%	132			260		(49	)%
Hepatitis C Franchise	13		347		(96	)%	(1		)	96		**
Other Brands	1,208		1,517		(20	)%	242			286		(15	)%

Total	$	16,588	$	15,327	8	%	$	9,243		$	8,467	9	%



**	In excess of +/- 100%

BRISTOL-MYERS SQUIBB COMPANY

CONSOLIDATED STATEMENTS OF EARNINGS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2018 AND 2017

(Unaudited, dollars and shares in millions except per share data)



	Three Months Ended September 30,						Nine Months Ended September 30,
	2018			2017			2018			2017
Net product sales	$	5,433		$	4,862		$	15,866		$	14,212
Alliance and other revenues	258			392			722			1,115
Total Revenues	5,691			5,254			16,588			15,327

Cost of products sold	1,648			1,579			4,857			4,413
Marketing, selling and administrative	1,104			1,163			3,215			3,435
Research and development	1,280			1,561			4,965			4,543
Other income (net)	(508		)	(232		)	(912		)	(1,497		)
Total Expenses	3,524			4,071			12,125			10,894

Earnings Before Income Taxes	2,167			1,183			4,463			4,433
Provision for Income Taxes	255			327			674			1,129

Net Earnings	1,912			856			3,789			3,304
Net Earnings/(Loss) Attributable to Noncontrolling Interest	11			11			29			(31		)
Net Earnings Attributable to BMS	$	1,901		$	845		$	3,760		$	3,335

Average Common Shares Outstanding:
Basic	1,632			1,639			1,633			1,648
Diluted	1,636			1,645			1,637			1,655

Earnings per Common Share
Basic	$	1.16		$	0.52		$	2.30		$	2.02
Diluted	1.16			0.51			2.30			2.02

Other income (net)
Interest expense	$	44		$	48		$	135		$	145
Investment income	(44		)	(32		)	(118		)	(87		)
Loss/(gain) on equity investments	(97		)	(5		)	244			(17		)
Provision for restructuring	45			28			102			207
Litigation and other settlements	11			—			10			(489		)
Equity in net income of affiliates	(22		)	(21		)	(73		)	(59		)
Divestiture (gains)/losses	(108		)	1			(178		)	(126		)
Royalties and licensing income	(338		)	(209		)	(1,058		)	(1,093		)
Transition and other service fees	—			(12		)	(5		)	(32		)
Pension and postretirement	(10		)	(19		)	(40		)	(29		)
Intangible asset impairment	—			—			64			—
Loss on debt redemption	—			—			—			109
Other	11			(11		)	5			(26		)
Other income (net)	$	(508	)	$	(232	)	$	(912	)	$	(1,497	)

BRISTOL-MYERS SQUIBB COMPANY

SPECIFIED ITEMS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2018 AND 2017

(Unaudited, dollars in millions)



	Three Months Ended September 30,						Nine Months Ended September 30,
	2018			2017			2018			2017
Impairment charges	$	—		$	1		$	10		$	128
Accelerated depreciation and other shutdown costs	13			—			30			3
Cost of products sold	13			1			40			131

Marketing, selling and administrative	—			—			1			—

License and asset acquisition charges	—			310			1,135			753
IPRD impairments	—			—			—			75
Site exit costs and other	18			64			57			232
Research and development	18			374			1,192			1,060

Loss/(gain) on equity investments	(97		)	—			244			—
Provision for restructuring	45			28			102			207
Litigation and other settlements	—			—			—			(481		)
Divestiture gains	(108		)	—			(176		)	(100		)
Royalties and licensing income	—			—			(75		)	(497		)
Pension and postretirement	27			22			95			91
Intangible asset impairment	—			—			64			—
Loss on debt redemption	—			—			—			109
Other income (net)	(133		)	50			254			(671		)

Increase/(decrease) to pretax income	(102		)	425			1,487			520

Income taxes on specified items	1			(41		)	(225		)	51
Income taxes attributed to U.S. tax reform	(20		)	—			(49		)	—
Income taxes	(19		)	(41		)	(274		)	51

Increase/(decrease) to net earnings	(121		)	384			1,213			571

Noncontrolling interest	—			—			—			(59		)

Increase/(decrease) to net earnings used for diluted Non-GAAP EPS calculation	$	(121	)	$	384		$	1,213		$	512

BRISTOL-MYERS SQUIBB COMPANY

RECONCILIATION OF CERTAIN GAAP LINE ITEMS TO CERTAIN NON-GAAP LINE ITEMS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2018 AND 2017

(Unaudited, dollars in millions)



	Three Months Ended September 30, 2018									Nine Months Ended September 30, 2018
	GAAP			Specified Items^(a)			Non- GAAP			GAAP			Specified Items^(a)			Non- GAAP
Gross Profit	$	4,043		$	13		$	4,056		$	11,731		$	40		$	11,771
Marketing, selling and administrative	1,104			—			1,104			3,215			(1		)	3,214
Research and development	1,280			(18		)	1,262			4,965			(1,192		)	3,773
Other income (net)	(508		)	133			(375		)	(912		)	(254		)	(1,166		)
Earnings Before Income Taxes	2,167			(102		)	2,065			4,463			1,487			5,950
Provision for Income Taxes	255			(19		)	274			674			(274		)	948
Noncontrolling interest	11			—			11			29			—			29

Net Earnings Attributable to BMS used for Diluted EPS Calculation	$	1,901		$	(121	)	$	1,780		$	3,760		$	1,213		$	4,973

Average Common Shares Outstanding - Diluted	1,636			1,636			1,636			1,637			1,637			1,637
Diluted Earnings Per Share	$	1.16		$	(0.07	)	$	1.09		$	2.30		$	0.74		$	3.04

Effective Tax Rate	11.8		%	1.5		%	13.3		%	15.1		%	0.8		%	15.9		%

	Three Months Ended September 30, 2017									Nine Months Ended September 30, 2017
	GAAP			Specified Items^(a)			Non- GAAP			GAAP			Specified Items^(a)			Non- GAAP
Gross Profit	$	3,675		$	1		$	3,676		$	10,914		$	131		$	11,045
Marketing, selling and administrative	1,163			—			1,163			3,435			—			3,435
Research and development	1,561			(374		)	1,187			4,543			(1,060		)	3,483
Other income (net)	(232		)	(50		)	(282		)	(1,497		)	671			(826		)
Earnings Before Income Taxes	1,183			425			1,608			4,433			520			4,953
Provision for Income Taxes	327			(41		)	368			1,129			51			1,078
Noncontrolling interest	11			—			11			(31		)	(59		)	28

Net Earnings Attributable to BMS used for Diluted EPS Calculation	$	845		$	384		$	1,229		$	3,335		$	512		$	3,847

Average Common Shares Outstanding - Diluted	1,645			1,645			1,645			1,655			1,655			1,655
Diluted Earnings Per Share	$	0.51		$	0.24		$	0.75		$	2.02		$	0.30		$	2.32

Effective Tax Rate	27.6		%	(4.7		)%	22.9		%	25.5		%	(3.7		)%	21.8		%



(a)	Refer to the Specified Items schedule for further details. Effective tax rate on the Specified Items represents the difference between the GAAP and Non-GAAP effective tax rate.

BRISTOL-MYERS SQUIBB COMPANY

NET CASH/(DEBT) CALCULATION

AS OF SEPTEMBER 30, 2018 AND JUNE 30, 2018

(Unaudited, dollars in millions)



	September 30, 2018			June 30, 2018
Cash and cash equivalents	$	5,408		$	4,999
Marketable securities - current	1,422			1,076
Marketable securities - non-current	2,017			2,117
Cash, cash equivalents and marketable securities	8,847			8,192
Short-term debt obligations	(1,620		)	(1,716		)
Long-term debt	(5,687		)	(5,671		)
Net cash position	$	1,540		$	805

EX-99.2 3 q32018ex992.htm CERTAIN SUPPLEMENTAL INFORMATION Exhibit

Exhibit 99.2

BRISTOL-MYERS SQUIBB COMPANY

QUARTERLY TREND ANALYSIS OF REVENUES

(Unaudited, dollars in millions)



Revenues	2017																					2018																	% Change				FX Impact
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr	Year	Qtr vs. Qtr		YTD vs. YTD		Qtr vs. Qtr		YTD vs. YTD
United States	$	2,738		$	2,865		$	5,603		$	2,864		$	8,467		$	2,891		$	11,358		$	2,778		$	3,230		$	6,008		$	3,235		$	9,243				13	%	9	%	—		—
Europe	1,146			1,188			2,334			1,262			3,596			1,392			4,988			1,406			1,408			2,814			1,365			4,179					8	%	16	%	(2	)%	7	%
Rest of the World	925			963			1,888			970			2,858			1,019			3,877			873			923			1,796			932			2,728					(4	)%	(5	)%	(6	)%	(1	)%
Other	120			128			248			158			406			147			553			136			143			279			159			438					1	%	8	%	N/A		N/A
Total	$	4,929		$	5,144		$	10,073		$	5,254		$	15,327		$	5,449		$	20,776		$	5,193		$	5,704		$	10,897		$	5,691		$	16,588				8	%	8	%	(2	)%	1	%

% of Revenues	2017																					2018
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr	Year
United States	55.5		%	55.7		%	55.6		%	54.5		%	55.2		%	53.1		%	54.7		%	53.5		%	56.6		%	55.1		%	56.8		%	55.7		%
Europe	23.3		%	23.1		%	23.2		%	24.0		%	23.5		%	25.5		%	24.0		%	27.1		%	24.7		%	25.8		%	24.0		%	25.2		%
Rest of the World	18.8		%	18.7		%	18.7		%	18.5		%	18.6		%	18.7		%	18.7		%	16.8		%	16.2		%	16.5		%	16.4		%	16.5		%
Other	2.4		%	2.5		%	2.5		%	3.0		%	2.7		%	2.7		%	2.6		%	2.6		%	2.5		%	2.6		%	2.8		%	2.6		%
Total	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%

BRISTOL-MYERS SQUIBB COMPANY

EARNINGS FROM OPERATIONS

(Unaudited, dollars and shares in millions except per share data)



	2017																					2018																	% Change
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr	Year	Qtr vs. Qtr		YTD vs. YTD
Net product sales	$	4,580		$	4,770		$	9,350		$	4,862		$	14,212		$	5,046		$	19,258		$	4,972		$	5,461		$	10,433		$	5,433		$	15,866				12	%	12	%
Alliance and other revenues	349			374			723			392			1,115			403			1,518			221			243			464			258			722					(34	)%	(35	)%
Total Revenues	$	4,929		$	5,144		$	10,073		$	5,254		$	15,327		$	5,449		$	20,776		$	5,193		$	5,704		$	10,897		$	5,691		$	16,588				8	%	8	%

Cost of products sold	1,265			1,569			2,834			1,579			4,413			1,681			6,094			1,584			1,625			3,209			1,648			4,857					4	%	10	%
Marketing, selling and administrative	1,085			1,187			2,272			1,163			3,435			1,316			4,751			980			1,131			2,111			1,104			3,215					(5	)%	(6	)%
Research and development	1,303			1,679			2,982			1,561			4,543			1,939			6,482			1,250			2,435			3,685			1,280			4,965					(18	)%	9	%
Other income (net)	(679		)	(586		)	(1,265		)	(232		)	(1,497		)	(185		)	(1,682		)	(400		)	(4		)	(404		)	(508		)	(912		)			**		(39	)%
Total Expenses	2,974			3,849			6,823			4,071			10,894			4,751			15,645			3,414			5,187			8,601			3,524			12,125					(13	)%	11	%

Earnings Before Income Taxes	$	1,955		$	1,295		$	3,250		$	1,183		$	4,433		$	698		$	5,131		$	1,779		$	517		$	2,296		$	2,167		$	4,463				83	%	1	%
Provision for Income Taxes	429			373			802			327			1,129			3,027			4,156			284			135			419			255			674					(22	)%	(40	)%
Net Earnings/(Loss)	$	1,526		$	922		$	2,448		$	856		$	3,304		$	(2,329	)	$	975		$	1,495		$	382		$	1,877		$	1,912		$	3,789				**		15	%
Net Earnings/(Loss) Attributable to Noncontrolling Interest	(48		)	6			(42		)	11			(31		)	(1		)	(32		)	9			9			18			11			29					—		**
Net Earnings/(Loss) Attributable to BMS	$	1,574		$	916		$	2,490		$	845		$	3,335		$	(2,328	)	$	1,007		$	1,486		$	373		$	1,859		$	1,901		$	3,760				**		13	%

Diluted Earnings/(Loss) per Common Share*	$	0.94		$	0.56		$	1.50		$	0.51		$	2.02		$	(1.42	)	$	0.61		$	0.91		$	0.23		$	1.13		$	1.16		$	2.30				**		14	%
Average Common Shares Outstanding - Diluted	1,671			1,650			1,660			1,645			1,655			1,635			1,652			1,640			1,636			1,638			1,636			1,637					(1	)%	(1	)%
Dividends declared per common share	$	0.39		$	0.39		$	0.78		$	0.39		$	1.17		$	0.40		$	1.57		$	0.40		$	0.40		$	0.80		$	0.40		$	1.20				3	%	3	%


	2017																					2018
% of Total Revenues	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr	Year
Gross Margin	74.3		%	69.5		%	71.9		%	69.9		%	71.2		%	69.2		%	70.7		%	69.5		%	71.5		%	70.6		%	71.0		%	70.7		%

Other Ratios
Effective tax rate	21.9		%	28.8		%	24.7		%	27.6		%	25.5		%	433.7		%	81.0		%	16.0		%	26.1		%	18.2		%	11.8		%	15.1		%

Other income (net)	2017																					2018																	% Change
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr	Year	Qtr vs. Qtr		YTD vs. YTD
Interest expense	$	45		$	52		$	97		$	48		$	145		$	51		$	196		$	46		$	45		$	91		$	44		$	135				(8	)%	(7	)%
Investment income	(26		)	(29		)	(55		)	(32		)	(87		)	(39		)	(126		)	(36		)	(38		)	(74		)	(44		)	(118		)			38	%	36	%
Loss/(gain) on equity investments	(7		)	(5		)	(12		)	(5		)	(17		)	(11		)	(28		)	(15		)	356			341			(97		)	244					**		**
Provision for restructuring	164			15			179			28			207			86			293			20			37			57			45			102					61	%	(51	)%
Litigation and other settlements	(484		)	(5		)	(489		)	—			(489		)	2			(487		)	—			(1		)	(1		)	11			10					N/A		**
Equity in net income of affiliates	(18		)	(20		)	(38		)	(21		)	(59		)	(16		)	(75		)	(24		)	(27		)	(51		)	(22		)	(73		)			5	%	24	%
Divestiture (gains)/losses	(127		)	—			(127		)	1			(126		)	(38		)	(164		)	(45		)	(25		)	(70		)	(108		)	(178		)			**		41	%
Royalties and licensing income	(199		)	(685		)	(884		)	(209		)	(1,093		)	(258		)	(1,351		)	(367		)	(353		)	(720		)	(338		)	(1,058		)			62	%	(3	)%
Transition and other service fees	(7		)	(13		)	(20		)	(12		)	(32		)	(5		)	(37		)	(4		)	(1		)	(5		)	—			(5		)			(100	)%	(84	)%
Pension and postretirement	1			(11		)	(10		)	(19		)	(29		)	28			(1		)	(11		)	(19		)	(30		)	(10		)	(40		)			(47	)%	38	%
Intangible asset impairment	—			—			—			—			—			—			—			64			—			64			—			64					—		N/A
Equity investment impairment	—			—			—			—			—			5			5			—			—			—			—			—					—		—
Loss on debt redemption	—			109			109			—			109			—			109			—			—			—			—			—					—		(100	)%
Other	(21		)	6			(15		)	(11		)	(26		)	10			(16		)	(28		)	22			(6		)	11			5					**		**
	$	(679	)	$	(586	)	$	(1,265	)	$	(232	)	$	(1,497	)	$	(185	)	$	(1,682	)	$	(400	)	$	(4	)	$	(404	)	$	(508	)	$	(912	)			**		(39	)%

Quarterly amounts may not add to the year-to-date totals due to rounding of individual calculations.

In excess of +/- 100%

BRISTOL-MYERS SQUIBB COMPANY

RECONCILIATION OF GAAP AND NON-GAAP GROWTH DOLLARS AND PERCENTAGES EXCLUDING FOREIGN EXCHANGE IMPACT

FOR THE PERIOD ENDED SEPTEMBER 30, 2018

(Unaudited, dollars in millions)



QUARTER-TO-DATE	2018			2017			Growth $			Growth %		Favorable / (Unfavorable) FX Impact $ *			2018 Excluding FX		Favorable / (Unfavorable) FX Impact % *		Growth % Excluding FX
Revenues	$	5,691		$	5,254		$	437		8	%	$	(76	)	$	5,767	(2	)%	10	%
Gross profit	4,043			3,675			368			10	%	N/A			N/A		N/A		N/A
Gross profit excluding specified items^(a)	4,056			3,676			380			10	%	N/A			N/A		N/A		N/A

Gross profit excluding specified items as a % of revenues	71.3		%	70.0		%

Marketing, selling and administrative	1,104			1,163			(59		)	(5	)%	15			1,119		1	%	(4	)%
Marketing, selling and administrative excluding specified items^(a)	1,104			1,163			(59		)	(5	)%	15			1,119		1	%	(4	)%

Marketing, selling and administrative excluding specified items as a % of revenues	19.4		%	22.1		%

Research and development	1,280			1,561			(281		)	(18	)%	3			1,283		—		(18	)%
Research and development excluding specified items^(a)	1,262			1,187			75			6	%	3			1,265		1	%	7	%

Research and development excluding specified items as a % of revenues	22.2		%	22.6		%

YEAR-TO-DATE	2018			2017			Growth $			Growth %		Favorable / (Unfavorable) FX Impact $ *			2018 Excluding FX		Favorable / (Unfavorable) FX Impact % *		Growth % Excluding FX
Revenues	$	16,588		$	15,327		$	1,261		8	%	$	232		$	16,356	1	%	7	%
Gross profit	11,731			10,914			817			7	%	N/A			N/A		N/A		N/A
Gross profit excluding specified items ^(a)	11,771			11,045			726			7	%	N/A			N/A		N/A		N/A

Gross profit excluding specified items as a % of revenues	71.0		%	72.1		%

Marketing, selling and administrative	3,215			3,435			(220		)	(6	)%	(40		)	3,175		(2	)%	(8	)%
Marketing, selling and administrative excluding specified items ^(a)	3,214			3,435			(221		)	(6	)%	(40		)	3,174		(2	)%	(8	)%

Marketing, selling and administrative excluding specified items as a % of revenues	19.4		%	22.4		%

Research and development	4,965			4,543			422			9	%	(28		)	4,937		—		9	%
Research and development excluding specified items ^(a)	3,773			3,483			290			8	%	(22		)	3,751		—		8	%

Research and development excluding specified items as a % of revenues	22.7		%	22.7		%

^(a)

Refer to the Specified Items schedule for further details.

Foreign exchange impacts were derived by applying the prior period average currency rates to the current period sales and expenses.

BRISTOL-MYERS SQUIBB COMPANY

WORLDWIDE REVENUES

QUARTERLY REVENUES TREND ANALYSIS

(Unaudited, dollars in millions)



	2017														2018													Growth $						% Change
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr		6 Months		3rd Qtr			9 Months		4th Qtr	Year	Qtr vs. Qtr			YTD vs. YTD			Qtr vs. Qtr		YTD vs. YTD
Prioritized Brands
Opdivo	$	1,127	$	1,195	$	2,322	$	1,265	$	3,587	$	1,361	$	4,948	$	1,511	$	1,627	$	3,138	$	1,793		$	4,931			$	528		$	1,344		42	%	37	%
Eliquis	1,101		1,176		2,277		1,232		3,509		1,363		4,872		1,506		1,650		3,156		1,577			4,733				345			1,224			28	%	35	%
Orencia	535		650		1,185		632		1,817		662		2,479		593		711		1,304		675			1,979				43			162			7	%	9	%
Sprycel	463		506		969		509		1,478		527		2,005		438		535		973		491			1,464				(18		)	(14		)	(4	)%	(1	)%
Yervoy	330		322		652		323		975		269		1,244		249		315		564		382			946				59			(29		)	18	%	(3	)%
Empliciti	53		55		108		60		168		63		231		55		64		119		59			178				(1		)	10			(2	)%	6	%
Established Brands
Baraclude	282		273		555		264		819		233		1,052		225		179		404		175			579				(89		)	(240		)	(34	)%	(29	)%
Sustiva Franchise^(a)	184		188		372		183		555		174		729		84		73		157		72			229				(111		)	(326		)	(61	)%	(59	)%
Reyataz Franchise	193		188		381		174		555		143		698		124		117		241		87			328				(87		)	(227		)	(50	)%	(41	)%
Hepatitis C Franchise	162		112		274		73		347		59		406		3		12		15		(2		)	13				(75		)	(334		)	**		(96	)%
Other Brands	499		479		978		539		1,517		595		2,112		405		421		826		382			1,208				(157		)	(309		)	(29	)%	(20	)%

Total	$	4,929	$	5,144	$	10,073	$	5,254	$	15,327	$	5,449	$	20,776	$	5,193	$	5,704	$	10,897	$	5,691		$	16,588			$	437		$	1,261		8	%	8	%



**	In excess of +/- 100%
(a)	The Sustiva Franchise includes sales of Sustiva, BMS's share of Atripla revenues in Europe, and U.S. Atripla royalty revenue beginning January 1, 2018.

BRISTOL-MYERS SQUIBB COMPANY

U.S. REVENUES

QUARTERLY REVENUES TREND ANALYSIS

(Unaudited, dollars in millions)



	2017														2018															% Change
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr			6 Months		3rd Qtr			9 Months			4th Qtr	Year	Qtr vs. Qtr		YTD vs. YTD
Prioritized Brands
Opdivo	$	761	$	768	$	1,529	$	778	$	2,307	$	795	$	3,102	$	938	$	1,024		$	1,962	$	1,141		$	3,103				47	%	35	%
Eliquis	699		703		1,402		717		2,119		768		2,887		885		979			1,864		917			2,781					28	%	31	%
Orencia	362		449		811		432		1,243		461		1,704		385		501			886		474			1,360					10	%	9	%
Sprycel	247		281		528		278		806		299		1,105		214		310			524		267			791					(4	)%	(2	)%
Yervoy	243		245		488		239		727		181		908		162		228			390		278			668					16	%	(8	)%
Empliciti	36		37		73		39		112		39		151		37		41			78		41			119					5	%	6	%
Established Brands
Baraclude	14		12		26		14		40		13		53		10		9			19		6			25					(57	)%	(38	)%
Sustiva Franchise^(a)	153		161		314		157		471		151		622		10		8			18		5			23					(97	)%	(95	)%
Reyataz Franchise	88		87		175		85		260		67		327		51		54			105		27			132					(68	)%	(49	)%
Hepatitis C Franchise	42		30		72		24		96		13		109		5		(2		)	3		(4		)	(1		)			**		**
Other Brands	93		92		185		101		286		104		390		81		78			159		83			242					(18	)%	(15	)%

Total^(b)	$	2,738	$	2,865	$	5,603	$	2,864	$	8,467	$	2,891	$	11,358	$	2,778	$	3,230		$	6,008	$	3,235		$	9,243				13	%	9	%



**	In excess of +/- 100%
(a)	In 2018, U.S. Sustiva Franchise revenues include sales of Sustiva only.
(b)	Includes United States and Puerto Rico.

BRISTOL-MYERS SQUIBB COMPANY

INTERNATIONAL REVENUES

QUARTERLY REVENUES TREND ANALYSIS

(Unaudited, dollars in millions)



	2017														2018													% Change
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr			2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr	Year	Qtr vs. Qtr		YTD vs. YTD
Prioritized Brands
Opdivo	$	366	$	427	$	793	$	487	$	1,280	$	566	$	1,846	$	573		$	603	$	1,176	$	652	$	1,828			34	%	43	%
Eliquis	402		473		875		515		1,390		595		1,985		621			671		1,292		660		1,952				28	%	40	%
Orencia	173		201		374		200		574		201		775		208			210		418		201		619				1	%	8	%
Sprycel	216		225		441		231		672		228		900		224			225		449		224		673				(3	)%	—
Yervoy	87		77		164		84		248		88		336		87			87		174		104		278				24	%	12	%
Empliciti	17		18		35		21		56		24		80		18			23		41		18		59				(14	)%	5	%
Established Brands
Baraclude	268		261		529		250		779		220		999		215			170		385		169		554				(32	)%	(29	)%
Sustiva Franchise^(a)	31		27		58		26		84		23		107		74			65		139		67		206				**		**
Reyataz Franchise	105		101		206		89		295		76		371		73			63		136		60		196				(33	)%	(34	)%
Hepatitis C Franchise	120		82		202		49		251		46		297		(2		)	14		12		2		14				(96	)%	(94	)%
Other Brands	406		387		793		438		1,231		491		1,722		324			343		667		299		966				(32	)%	(22	)%

Total^(b)	$	2,191	$	2,279	$	4,470	$	2,390	$	6,860	$	2,558	$	9,418	$	2,415		$	2,474	$	4,889	$	2,456	$	7,345			3	%	7	%



**	In excess of +/- 100%
(a)	The Sustiva Franchise includes BMS's share of Atripla revenues in Europe, and U.S. Atripla royalty revenue beginning January 1, 2018.
(b)	The foreign exchange impact on international revenues was unfavorable 3% for the third quarter and favorable 3% year to date. The foreign exchange impact on Prioritized Brands is included below.

		Quarter-to-Date			Year-to-Date
		Revenue Change %	Favorable/ (Unfavorable) FX Impact %	Revenue Change % Excluding FX	Revenue Change %	Favorable/ (Unfavorable) FX Impact %	Revenue Change % Excluding FX
	Opdivo	34%	(5)%	39%	43%	4%	39%
	Eliquis	28%	(2)%	30%	40%	6%	34%
	Orencia	1%	(4)%	5%	8%	2%	6%
	Sprycel	(3)%	(3)%	—	—	3%	(3)%
	Yervoy	24%	(6)%	30%	12%	3%	9%

BRISTOL-MYERS SQUIBB COMPANY

SPECIFIED ITEMS

(Unaudited, dollars in millions)



	2017																					2018
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr	Year
Impairment charges	$	—		$	127		$	127		$	1		$	128		$	18		$	146		$	10		$	—		$	10		$	—		$	10
Accelerated depreciation and other shutdown costs	—			3			3			—			3			—			3			3			14			17			13			30
Cost of products sold	—			130			130			1			131			18			149			13			14			27			13			40

Marketing, selling and administrative	—			—			—			—			—			1			1			1			—			1			—			1

License and asset acquisition charges	50			393			443			310			753			377			1,130			60			1,075			1,135			—			1,135
IPRD impairments	75			—			75			—			75			—			75			—			—			—			—			—
Site exit costs and other	72			96			168			64			232			151			383			20			19			39			18			57
Research and development	197			489			686			374			1,060			528			1,588			80			1,094			1,174			18			1,192

Loss/(gain) on equity investments	—			—			—			—			—			—			—			(15		)	356			341			(97		)	244
Provision for restructuring	164			15			179			28			207			86			293			20			37			57			45			102
Litigation and other settlements	(481		)	—			(481		)	—			(481		)	—			(481		)	—			—			—			—			—
Divestiture gains	(100		)	—			(100		)	—			(100		)	(26		)	(126		)	(43		)	(25		)	(68		)	(108		)	(176		)
Royalties and licensing income	—			(497		)	(497		)	—			(497		)	—			(497		)	(50		)	(25		)	(75		)	—			(75		)
Pension and postretirement	33			36			69			22			91			71			162			31			37			68			27			95
Intangible asset impairment	—			—			—			—			—			—			—			64			—			64			—			64
Loss on debt redemption	—			109			109			—			109			—			109			—			—			—			—			—
Other income (net)	(384		)	(337		)	(721		)	50			(671		)	131			(540		)	7			380			387			(133		)	254

Increase/(decrease) to pretax income	(187		)	282			95			425			520			678			1,198			101			1,488			1,589			(102		)	1,487

Income taxes on specified items	72			20			92			(41		)	51			(138		)	(87		)	(8		)	(218		)	(226		)	1			(225		)
Income taxes attributed to U.S. tax reform	—			—			—			—			—			2,911			2,911			(32		)	3			(29		)	(20		)	(49		)
Income taxes	72			20			92			(41		)	51			2,773			2,824			(40		)	(215		)	(255		)	(19		)	(274		)

Increase/(decrease) to net earnings	(115		)	302			187			384			571			3,451			4,022			61			1,273			1,334			(121		)	1,213

Noncontrolling interest	(59		)	—			(59		)	—			(59		)	—			(59		)	—			—			—			—			—

Increase/(decrease) to net earnings used for diluted Non-GAAP EPS calculation	$	(174	)	$	302		$	128		$	384		$	512		$	3,451		$	3,963		$	61		$	1,273		$	1,334		$	(121	)	$	1,213

BRISTOL-MYERS SQUIBB COMPANY

RECONCILIATION OF CERTAIN GAAP LINE ITEMS TO CERTAIN NON-GAAP LINE ITEMS

(Unaudited, dollars in millions)



	2017																					2018
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr	Year
Gross Profit	$	3,664		$	3,575		$	7,239		$	3,675		$	10,914		$	3,768		$	14,682		$	3,609		$	4,079		$	7,688		$	4,043		$	11,731
Specified items^(a)	—			130			130			1			131			18			149			13			14			27			13			40
Gross profit excluding specified items	3,664			3,705			7,369			3,676			11,045			3,786			14,831			3,622			4,093			7,715			4,056			11,771

Marketing, selling and administrative	1,085			1,187			2,272			1,163			3,435			1,316			4,751			980			1,131			2,111			1,104			3,215
Specified items^(a)	—			—			—			—			—			(1		)	(1		)	(1		)	—			(1		)	—			(1		)
Marketing, selling and administrative excluding specified items	1,085			1,187			2,272			1,163			3,435			1,315			4,750			979			1,131			2,110			1,104			3,214

Research and development	1,303			1,679			2,982			1,561			4,543			1,939			6,482			1,250			2,435			3,685			1,280			4,965
Specified items^(a)	(197		)	(489		)	(686		)	(374		)	(1,060		)	(528		)	(1,588		)	(80		)	(1,094		)	(1,174		)	(18		)	(1,192		)
Research and development excluding specified items	1,106			1,190			2,296			1,187			3,483			1,411			4,894			1,170			1,341			2,511			1,262			3,773

Other income (net)	(679		)	(586		)	(1,265		)	(232		)	(1,497		)	(185		)	(1,682		)	(400		)	(4		)	(404		)	(508		)	(912		)
Specified items^(a)	384			337			721			(50		)	671			(131		)	540			(7		)	(380		)	(387		)	133			(254		)
Other income (net) excluding specified items	(295		)	(249		)	(544		)	(282		)	(826		)	(316		)	(1,142		)	(407		)	(384		)	(791		)	(375		)	(1,166		)



(a)	Refer to the Specified Items schedule for further details.

BRISTOL-MYERS SQUIBB COMPANY

RECONCILIATION OF GAAP TO NON-GAAP EPS

(Unaudited, dollars in millions)



	2017																					2018
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr	Year
Earnings before income taxes	$	1,955		$	1,295		$	3,250		$	1,183		$	4,433		$	698		$	5,131		$	1,779		$	517		$	2,296		$	2,167		$	4,463
Specified items^(a)	(187		)	282			95			425			520			678			1,198			101			1,488			1,589			(102		)	1,487
Earnings before income taxes excluding specified items	1,768			1,577			3,345			1,608			4,953			1,376			6,329			1,880			2,005			3,885			2,065			5,950

Provision for income taxes	429			373			802			327			1,129			3,027			4,156			284			135			419			255			674
Tax on specified items^(a)	72			20			92			(41		)	51			(138		)	(87		)	(8		)	(218		)	(226		)	1			(225		)
Income taxes attributed to U.S. tax reform^(a)	—			—			—			—			—			2,911			2,911			(32		)	3			(29		)	(20		)	(49		)
Provision for income taxes excluding tax on specified items and income taxes attributed to U.S. tax reform	357			353			710			368			1,078			254			1,332			324			350			674			274			948

Net Earnings/(Loss) Attributable to Noncontrolling Interest	(48		)	6			(42		)	11			(31		)	(1		)	(32		)	9			9			18			11			29
Specified items^(a)	(59		)	—			(59		)	—			(59		)	—			(59		)	—			—			—			—			—
Net Earnings/(Loss) Attributable to Noncontrolling Interest excluding specified items	11			6			17			11			28			(1		)	27			9			9			18			11			29

Net Earnings/(Loss) Attributable to BMS used for Diluted EPS Calculation - GAAP	1,574			916			2,490			845			3,335			(2,328		)	1,007			1,486			373			1,859			1,901			3,760
Specified items^(a)	(174		)	302			128			384			512			3,451			3,963			61			1,273			1,334			(121		)	1,213
Net Earnings Attributable to BMS used for Diluted EPS Calculation excluding specified items - Non-GAAP	1,400			1,218			2,618			1,229			3,847			1,123			4,970			1,547			1,646			3,193			1,780			4,973

Weighted-average Common Shares Outstanding - Diluted- GAAP	1,671			1,650			1,660			1,645			1,655			1,635			1,652			1,640			1,636			1,638			1,636			1,637
Weighted-average Common Shares Outstanding - Diluted- Non-GAAP	1,671			1,650			1,660			1,645			1,655			1,642			1,652			1,640			1,636			1,638			1,636			1,637

Diluted Earnings/(Loss) Per Share - GAAP	$	0.94		$	0.56		$	1.50		$	0.51		$	2.02		$	(1.42	)	$	0.61		$	0.91		$	0.23		$	1.13		$	1.16		$	2.30
Diluted Earnings/(Loss) Per Share Attributable to Specified Items	(0.10		)	0.18			0.08			0.24			0.30			2.10			2.40			0.03			0.78			0.82			(0.07		)	0.74
Diluted Earnings Per Share - Non-GAAP	$	0.84		$	0.74		$	1.58		$	0.75		$	2.32		$	0.68		$	3.01		$	0.94		$	1.01		$	1.95		$	1.09		$	3.04

Effective Tax Rate	21.9		%	28.8		%	24.7		%	27.6		%	25.5		%	433.7		%	81.0		%	16.0		%	26.1		%	18.2		%	11.8		%	15.1		%
Specified items^(a)	(1.7		)%	(6.4		)%	(3.5		)%	(4.7		)%	(3.7		)%	(415.2		)%	(60.0		)%	1.2		%	(8.6		)%	(0.9		)%	1.5		%	0.8		%
Effective Tax Rate excluding specified items	20.2		%	22.4		%	21.2		%	22.9		%	21.8		%	18.5		%	21.0		%	17.2		%	17.5		%	17.3		%	13.3		%	15.9		%

(a)

Refer to the Specified Items schedule for further details. Effective tax rate on the Specified Items represents the difference between the GAAP and Non-GAAP effective tax rate.

BRISTOL-MYERS SQUIBB COMPANY

SELECTED BALANCE SHEET INFORMATION

(Unaudited, dollars in millions)



	March 31, 2017			June 30, 2017			September 30, 2017			December 31, 2017			March 31, 2018			June 30, 2018			September 30, 2018			December 31, 2018
Cash and cash equivalents	$	3,910		$	3,470		$	4,644		$	5,421		$	5,342		$	4,999		$	5,408
Marketable securities - current	2,199			3,035			2,478			1,391			1,428			1,076			1,422
Marketable securities - non-current	2,685			2,580			2,526			2,480			2,252			2,117			2,017
Cash, cash equivalents and marketable securities	8,794			9,085			9,648			9,292			9,022			8,192			8,847

Short-term debt obligations	(1,197		)	(1,306		)	(1,461		)	(987		)	(1,925		)	(1,716		)	(1,620		)
Long-term debt	(7,237		)	(6,911		)	(6,982		)	(6,975		)	(5,775		)	(5,671		)	(5,687		)
Net cash position	$	360		$	868		$	1,205		$	1,330		$	1,322		$	805		$	1,540



BRISTOL-MYERS SQUIBB COMPANY
2018 FULL YEAR PROJECTED DILUTED EPS FROM OPERATIONS
EXCLUDING PROJECTED SPECIFIED ITEMS



	Full Year 2018
	Full Year 2018

	Pre-tax		Tax		After-tax
Projected Diluted Earnings Attributable to Shareholders per Common Share - GAAP					$3.05 to $3.15

Projected Specified Items:
Restructuring, accelerated depreciation and other exit costs ⁽¹⁾	0.16		0.03		0.13
Divestiture gains and licensing income	(0.21	)	(0.05	)	(0.16	)
Research and development license and asset acquisition charges	0.69		0.14		0.55
Pension charges	0.09		0.02		0.07
Loss/(gain) on equity investments	0.15		(0.01	)	0.16
Other	0.04		0.04		—
Total	0.92		0.17		0.75

Projected Diluted Earnings Attributable to Shareholders per Common Share - Non-GAAP					$3.80 to $3.90

⁽¹⁾ Includes items recognized in Cost of products sold, Research and development and Other income (net).

The following table summarizes the company's 2018 financial guidance:

Line item

GAAP

Non-GAAP

Worldwide revenues

Increasing in the high-single digits

Gross margin as a percent of revenue

Approximately 71%

Marketing, selling and administrative expense

Decreasing in the low- to mid-single digit range

Research and development expense

Increasing in the low-single digits

Increasing in the high-single digits

Effective tax rate

Approximately 16.5%

Approximately 17%



The GAAP financial results for the full year 2018 will include specified items, including charges associated with restructuring, downsizing and streamlining worldwide operations, gains/losses on divestitures and equity investments, license and asset acquisition charges, pension charges and other specified items that have not yet been identified and quantified, including litigation and other settlements, licensed asset impairments and finalization of the deemed repatriation tax, among other items. For a fuller discussion of items that could impact full year GAAP results, as well as the use of non-GAAP financial information, see Bristol-Myers Squibb Reports Third Quarter 2018 Financial Results, October 25, 2018 including “2018 Financial Guidance” and “Use of non-GAAP Financial Information” therein.

GRAPHIC 4 bmslogoq22017a01.jpg GRAPHIC begin 644 bmslogoq22017a01.jpg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end